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Abstract: There is a constant need for new therapies against multidrug resistant (MDR) 
cancer. An attractive strategy is to develop chelators that display significant antitumor activity 
in multidrug resistant cancer cell lines overexpressing the drug efflux pump P-glycoprotein. In 
this study we used a panel of sensitive and MDR cancer cell lines to evaluate the toxicity of 
picolinylidene and salicylidene thiosemicarbazone, arylhydrazone, picolinylidene and 
salicylidene hydrazino-benzothiazole derivatives. Our results confirm the collateral sensitivity 
of MDR cells to isatin-β-thiosemicarbazones, and identify several chelator scaffolds with a 
potential to overcome multidrug resistance. Analysis of structure-activity-relationships within 
the investigated compound library indicates that NNS and NNN donor chelators show 
superior toxicity as compared to ONS derivatives regardless of the resistance status of the 
cells. 
 
1. Introduction 
Cancer is the second highest cause of death in industrialized countries [1,2]. Currently a broad 
range of diverse compounds with different mechanisms of anticancer activity is available for 
treatment [3]. Despite the diversity of drugs, cancer often proves incurable due to the 
development of drug resistance [2]. Moreover, cancer cells that develop resistance against a 
single cytotoxic agent show cross-resistance to structurally and mechanistically unrelated 
drugs [3]. Multidrug resistance (MDR) can emerge as a result of reduced uptake or increased 
efflux of cytostatic agents – the latter is mediated by ATP-binding-cassette (ABC) proteins, 
primarily by P-glycoprotein (P-gp), which confers resistance to a wide variety of compounds 
[3–7]. There is a constant need for novel chemotherapeutics with marked and selective 
antitumor activity that can overcome resistance to established therapies.  
The increased proliferation of cancer cells results in an elevated demand for metal ions, which 
creates a vulnerability that can be exploited therapeutically [8–11]. The toxicity of chelators is 
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mediated by the perturbation of intracellular metal homeostasis, the formation of redox active 
complexes, which generate reactive oxygen species (ROS), or the inhibition of 
metalloproteins such as ribonucleotide reductase (RR) [8,12,13]. Several chelators targeting 
cell-cycle progression and DNA synthesis have been reported as potentially active anticancer 
agents [9,12–15]. Since the first report of the moderate antileukemic activity of 2-formyl thio-
semicarbazone in 1956 [16], the chemical space around thiosemicarbazones (TSCs) with 
anticancer activity has been explored intensely. The most investigated TSC is Triapine, a 
tridentate α-N-pyridyl thiosemicarbazone (Figure 1, upper middle panel). Triapine is a potent 
RR inhibitor currently undergoing phase I and II clinical trials [17–19]. While the clinical 
efficacy of Triapine awaits confirmation, in vitro experiments have suggested that Triapine is 
subject to MDR, as it is recognized and transported by P-gp [20,21]. Substitution on the 
terminal nitrogen (N4) of the TSC moiety was reported to increase toxicity of TSC derivatives 
[21–23]. The terminally dimethylated TSC di-2-pyridylketone-4,4,-dimethyl-3-
thiosemicarbazone (Dp44mT, Figure 1, upper middle panel) has even been shown to exhibit a 
paradoxical hypertoxicity against the P-gp-overexpressing cervix carcinoma cell line KB-V1 
as compared to its parental cell line KB-3-1 [8,24]. In order to circumvent transporter 
mediated resistance, inhibiting the transporters appeared to be a valuable approach [25–33]. 
Despite promising in vitro results, successful translation of MDR transporter inhibition to the 
clinic remains elusive [25,34–38]. Compounds showing increased toxicity against MDR cells 
represent a promising strategy to overcome resistance in cancer [39]. The analysis of NCI’s 
Developmental Therapeutics Program (DTP) drug screening data has led to the identification 
of a series of “MDR-selective” compounds whose toxicity was positively correlated with P-gp 
expression across the NCI60 cells representing tumor types of different tissue origins [40–42]. 
The toxicity of MDR-selective compounds is indeed paradoxically increased in P-gp-
expressing MDR cells and is abrogated in the presence of P-gp inhibitors [15,40], revealing 
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that in contrast to the export of toxic substrates, P-gp can directly sensitize MDR cells 
[15,21,40,43]. Interestingly, the structurally diverse MDR-selective compounds share the 
ability to chelate metal ions. In particular, there is a strong link between the 
thiosemicarbazone backbone and MDR selective toxicity, as exemplified by several isatin-β-
thiosemicarbazones including NSC73306 (1a, Figure 1, upper left panel), NSC658339, 
NSC716765, NSC716766, NSC716768, NSC716771 and NSC716772 (for structures, see 
Table S1) [15,21,40,43,44]. In addition to these TSCs the pharmacogenomic approach also 
identified a benzothiazole (NSC693630, Figure 1, upper middle panel) as a candidate MDR-
selective agent [15]. The pyrimidinylhydrazone VP035 (Figure 1, upper right panel) has been 
reported to show selective toxicity towards MDR cell lines, yet in a P-gp independent manner 
[13]. 
In this study we characterize the anticancer activity of compounds designed around these five 
chelators possessing variable MDR-selective toxicity. The MDR-selective isatin-β-
thiosemicarbazone 1a (NSC73306) is an ONS donor chelator, Dp44mT and Triapine are NNS 
donor chelators; the benzothiazole NSC693630 is able to bind metal ions via an NNS or NNN 
coordination mode [15], and the arylhydrazone VP035 is an NNN donor chelator [13,45,46].  
In particular, our aim was to explore the chemical space around these compounds with regard 
to toxicity and MDR selectivity (Figure 1). We designed a focused library containing 
picolinylidene TSCs (class II), salicylidene TSCs (class III), in which respective chemical 
entities of the confirmed MDR-selective compounds (Figure 1, upper panels) are retained. To 
study derivatives of VP035, several N-hetero-arylhydrazones (class IV) were investigated. 
Picolinylidene (class V) and salicylidene (class VI) hydrazino-benzothiazoles were included 
in the library as derivatives of the hydrazino-benzothiazole NSC693630. Finally, various 
aspects of the chemical entities associated with MDR-selective activities were combined 
(class VII). 
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The compound library was tested for in vitro antiproliferative activity in six human cancer 
cell lines, including the drug sensitive and MDR ovarian carcinoma (A2780, A270adr), cervix 
carcinoma (KB-3-1, KB-V1) and uterine sarcoma (MES-SA, MES-SA/Dx5) cell lines. 
 
2. Results 
2.1. Design and synthesis of a focused chelator library 
Several attempts have been made to elucidate the structural features that are responsible for 
the MDR-selective toxicity of isatin-β-thiosemicarbazones. The current understanding of the 
structure activity relationship of MDR selective isatin-β-TSCs suggests a beneficial effect of 
an aromatic moiety at N4 [21,39]. Similarly, introduction of a phenyl substituent to the N4 
position has been shown to increase the toxicity of dipyridylketone TSCs to a comparable 
extent as terminal dimethylation [23,47]. In contrast to Dp44mT and NSC73306, the toxicity 
of the terminally unsubstituted NNS thiosemicarbazone Triapine is attenuated by P-gp 
[20,21,48].  
The library consists of three TSC classes (I-III), all of which possess an aromatic moiety at 
N4. Since the current understanding of the SAR additionally suggests a beneficial effect of 
either electron withdrawing or donating groups in the para position of the aromatic ring for 
selective activity towards MDR cell lines [39,44], compounds with nitro, methyl, and 
methoxy groups in this position were included in the library (Figure 2).  
In addition to the reported TSC compounds 1a [15,21,40,43,44], the N4 para tolyl derivative 
1c [44] and the N4 para nitrophenyl derivative 1d [44], we synthesized a new 5-
trifluormethoxyisatin derivative 1b. The N4 meta-trifluormethyl derivative 1e was 
commercially available (box I in Figure 2). In order to investigate the effect of a terminal 
aromatic substitution of the TSC moiety on toxicity and MDR selectivity of related 
derivatives, picolinylidene TSCs (Class II) were prepared with the same terminal substituents 
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as present in the MDR selective isatin-β-TSCs (2f, 2j, box II in Figures 1, 2). Substitutions at 
the imino carbon have been suggested to affect the toxicity of Schiff bases [13,49–52]. 
Therefore we also included the corresponding methylated derivatives in our study (2c, 2g, box 
II in Figures 1, 2). Additionally, the acetaniline derivative 2p was prepared, which is an NNS-
donor TSC like 2g, but has an anilinic NH2 instead of the ring-incorporated pyridinyl 
nitrogen. In order to increase the similarity of the new compounds to the MDR selective 
isatin-β-TSC compounds, we retained the ONS donor set of the isatin TSCs by replacing the 
pyridine moieties with salicylic residues (3b, 3c, box III in Figures 1, 2). As depicted in 
Scheme 1, thiosemicarbazones were obtained by an acid catalyzed Schiff base condensation 
of the particular thiosemicarbazide (C-1, C-2, or C-3) with the corresponding ketone, in good 
to moderate yields. C-1 to C-3 were prepared from the corresponding isothiocyanates upon 
reaction with hydrazine [44,53]. 
 
Arylhydrazones (class IV) and benzothiazoles (classes V, VI) have been introduced as 
alternatives to thiosemicarbazones, since TSCs exhibit pharmacological side effects due to the 
putative liberation of H2S during their metabolism [54,55]. Similar to thiosemicarbazones, 
these compound classes also provide the possibility to chelate metal ions, which has been 
suggested to be an important feature in their mechanism of action [13,45,46]. For a systematic 
comparison to the previous compounds (boxes II and III, Figures 1, 2), the respective 
picolinylidene (5a, 5b, 5c, box V, Figures 1, 2), acetaniline (5d) and salicylidene hydrazino-
benzothiazoles (6a, 6b, box VI, Figures 1, 2) were obtained by reacting the keto components 
with the commercially available 2-hydrazinobenzothiazole under the same acid catalyzed 
conditions as applied for the TSCs and provided the products in good yields (Scheme 1). As 
depicted in Figures 1 and 2, benzothiazoles can also chelate metal ions via an NNN binding 
mode, similar to arylhydrazones. The latter compound class has been suggested as yet another 
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alternative to overcome the metabolic instability of TSCs [55]. In order to include more NNN 
donors into the study, the previously reported arylhydrazones 4a-c [13] were incorporated to 
the study and the commercially available arylhydrazones 4d-h (box IV, Figure 1, 2) were 
purchased 
To further increase the similarity of the newly designed compounds to 1a, chemical entities 
were combined in the four compounds presented in box VII (Figure 2): in 7a the non-isatin 
moiety of 1a is dimerized. This compound was obtained by reaction of the 4-methoxyphenyl-
isothiocyanat with a half-equimolar amount of hydrazine. Two compounds were prepared to 
combine the chemical entities of 1a with the hydrazinobenzothiazole compound class. For 
these, either 4-methoxyphenylisothiocyanat or isatin were reacted with the 
hydrazinobenzothiazole, to provide compounds 7b and 7c, respectively. 7d is an 
arylhydrazone, obtained in an acid catalyzed condensation of isatin and 4-hydrazinyl-6-
methoxypyrimidine. 
In addition to the synthesized compounds, the library was extended with further commercially 
available compounds (1e, 2a, 2b, 2d, 2h, 2i, 2l, 2m, 2n, 2o, 3a, 3d, 3e, 3f, 3g, 4d, 4e, 4f, 4g, 
4h, 6c, 6d, 6e, 6f, 6g). For all compounds included in this study, the logD7.4 values, total polar 
surface area (TPSA), as well as the strongest pKa and pKb values were predicted with the 
ChemAxon software [56] (Supplementary tables S2-S6). 
 
2.2. Assessment of cytotoxicity in an MDR cell panel 
The cytotoxic activity of the compounds was investigated in a panel of parental (sensitive) 
and MDR cancer cells. The ovarian carcinoma cell line A2780 and the uterine sarcoma cell 
line MES-SA were compared to their doxorubicin-selected counterparts A2780adr and MES-
SA/Dx5, respectively [57–59], while the cervix carcinoma cell line KB-3-1 was compared to 
the vinblastine-selected line KB-V1 [60,61]. In addition, toxicity of selected active derivatives 
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was also evaluated in non-malignant HFF cells (Figure S1). As detailed in the experimental 
section, cytotoxicity of the compounds was measured using the MTT viability assay. In order 
to avoid a putative interaction of the investigated compounds with the assay reagent, the 
medium containing the test compound was removed before adding the reagent. Furthermore, 
no reaction could be observed in cell-free mixtures of compound solution and assay reagent. 
To exclude assay dependent results, MES-SA and MES-SA/Dx5 cells were engineered to 
stably express the mCherry fluorescent protein [62,63]. Therefore, the cell-killing effect of the 
test-compounds could additionally be investigated by fluorescent measurements avoiding 
putative side reactions with assay reagents [64]. As apparent from Figure S2, the two methods 
provided concordant results. Furthermore, Figure S2 highlights results obtained for 
hydroxyphenylhydrazone compounds, which have been reported to frequently disturb several 
diverse in vitro assays [65,66].  
To identify whether the toxicity of the compounds is influenced by the activity of the 
multidrug transporter, the effect of the P-gp-inhibitor Tariquidar was also evaluated.  
 
2.3. Confirmation of MDR selective activity of isatin-β-thiosemicarbazones (1a – 1e) 
Figure 3 shows the differential effect of the P-gp-substrate Triapine and the MDR-selective 
compounds 1a and 1d in a cell line pair of MDR and parental cells. While the toxicity of 
Triapine is reduced by the transporter (Figure 3A), there is an increased sensitivity of the P-
gp-positive MES-SA/Dx5 cells to 1a (Figure 3B) and 1d (Figure 3C) [44]. In the presence of 
the efflux pump inhibitor Tariquidar both resistance to Triapine and increased sensitivity to 
the MDR-selective compounds 1a and 1d are reverted to control levels measured in MES-SA 
cells. The fraction of IC50 values obtained in P-gp negative vs. positive cells serves as a 
quantification of the MDR selective effect (selectivity ratio, SR). Figure 3D shows the SR 
values for the isatin-β-thiosemicarbazones 1a – 1e. While the results of compound 1a are in 
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good agreement with the literature [15,21,40,43,44], the magnitude of MDR selectivity of the 
N4 para tolyl derivative 1c and the N4 para nitrophenyl derivative 1d is much lower in our 
test system (compared to reported SR values of 9.2 for 1c and 8.3 for 1d [44]). In fact, 1c is 
not selective in KB-V1 vs. KB-3-1 and A2780adr vs. A2780 cells. 
According to our current understanding of the SAR of isatin-β-thiosemicarbazones, 
substituents at the 5 position of the isatin moiety are tolerated, while meta substituents in the 
terminal phenyl ring have been described to have a detrimental effect on selective toxicity 
[39]. The two novel TSC derivatives, containing a trifluormethoxygroup in the 5-position of 
the isatin moiety (as present in 1b) or a trifluormethyl substituent at the terminal phenyl ring 
(as present in 1e) are consistent with this general conclusion (Figure 3D, Table S2). The P-gp 
inhibitor Tariquidar (TQ) abolished selectivity between the cell lines, proving that the 
cytotoxic activity of 1a, 1b, 1d and 1e is indeed potentiated by P-gp. Another characteristic of 
MDR-selective compounds is their ability to eliminate expression of P-gp and thus re-
sensitize cells to chemotherapy [43]. Long-term exposure of MES-SA/Dx5 cells to 
compounds 1a, 1c or 1d resulted in the elimination of P-gp-expressing cells, confirming the 
selective toxicity of these compounds to MDR cells (Figures 3 E-H, S2). 
 
2.4. Evaluation of selective toxicity in the compound library 
After confirming the MDR-selective toxicity associated with the isatin-β-thiosemicarbazone 
structures, we evaluated the activity of the compounds compiled in the focused library. As 
shown in Figures 1 and 2, the library combines several chemical motives that have been 
associated with MDR selective activity (such as the N4 substitution patterns and donor atom 
sets). The toxicity of the compounds was found to be similar across the cell lines, yielding 
IC50 values in the submicromolar to micromolar range. Similarly to the parent compounds (1a 
– 1d), several derivatives showed a significantly increased toxicity against some of the MDR 
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cells (Table 1). The picolinylidene TSC 2c and the salicylidene benzothiazoles 6a and 6b were 
significantly more toxic to MES-SA/Dx5 than to MES-SA cells; 2g showed selectivity in KB-
V1 cells over KB-3-1; the arylhydrazones 4c and 4b showed selective activity in MES-
SA/Dx5 over MES-SA cells as well as in A2780adr over A2780 cells [13]; the benzothiazoles 
5b and 5a, as well as the salicylidene TSC 3a showed selectivity in MES-SA/Dx5 over MES-
SA cells (Tables 1, S2 - S6, Figures S2 - S6). It is striking that picolinylidene compounds 
containing a methyl group at the imino carbon (2c, 2g, 4b, 5b) exhibit very high SR values. 
Yet, the selective toxicity of these compounds towards P-gp-expressing cells could not be 
confirmed in all of the MDR cell line pairs. Also in contrast to the isatin-β-
thiosemicarbazones, inhibition of P-gp did not abolish selectivity of these derivatives, 
suggesting that the hypersensitivity of the MDR cells to these compounds is not exclusively 
linked to P-gp. 
 
2.5. Toxicity of picolinylidene Schiff bases in MES-SA and MES-SA/Dx5 cells 
Based on studies with chloro- and methoxysubstituted derivatives, it has been suggested that 
substituents in the para position of the N4-phenyl group of isatin-β-TSCs improve MDR 
selective toxicity, while the meta and ortho positions were found to be not beneficial [39,44]. 
As shown in Figure 4, various methyl substitutions at the N4-phenyl ring of picolinylidene 
TSCs follow the same trend: the toxicity on P-gp-negative MES-SA cells is similar for ortho- 
and meta-substituted picolinylidene TSC derivatives (2i and 2h, respectively), but is reduced 
for the para tolyl TSC (2g). Conversely, in case of the P-gp-positive MES-SA/Dx5 cells the 
toxicity increases from ortho- (2i) to meta- (2h) to para-substituted (2g) derivatives. In case 
of trifluoromethyl substituents at the N4-phenyl ring the ortho-derivatives 2n and 2o were 
more toxic than the meta-substituted derivatives 2l and 2m in both investigated cell lines (the 
corresponding para-derivatives were unfortunately not available). The methyl and 
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trifluoromethyl substituted derivatives show a similar toxicity in case of ortho substitution (2i 
vs. 2o), while in case of the meta-substituted derivatives, the tolyl TSC 2h exhibits higher 
toxicity than the corresponding trifluormethyl derivative 2m. No strong correlation was found 
between the toxicity data of compounds presented in Figure 4 with calculated chemical 
properties (Table S7). 
 
2.6. Effect of imino carbon methylation on the toxicity of the synthesized Schiff bases 
Literature data suggest that the imino carbon of thiosemicarbazones [68], aroylhydrazones 
[51], arylhydrazones [13] and benzothiazoles [49,50] may be a sensitive position for fine-
tuning the biological activity of these Schiff bases. The role of imino carbon methylation on 
the toxicity of the investigated compounds is also evident from the structure-activity matrix 
shown in Figure 4. Figures 5A and B show the toxicity data of matched molecular pairs 
(MMPs) with and without imino carbon methylation. TSCs, benzothiazoles and 
arylhydarzones are shown with NNS (Figure 5A) and NNN (Figure 5B) donor atom sets. 
Introduction of a methyl group to the imino carbon results in increased toxicity in all 
investigated cell lines in two of the four investigated NNS donor MMPs (namely compounds 
2f vs. 2g and 5a vs. 5b). For the N4-ortho-trifluormethylphenyl TSC MMP, the imino-
methylated derivative 2o showed a higher toxicity than the desmethyl counterpart 2n in MES-
SA cells, while MES-SA/Dx5 cells reacted to both compounds with the same sensitivity. In 
the fourth MMP the methylated derivative 2m was actually less toxic than the desmethyl 
derivative 2l. In case of the NNN donor containing compounds, increased toxicity upon 
methylation could only be observed for the previously reported pyrimidinylhydrazone 4b over 
4a [13], while toxicity of the arylhydrazones 4e and 4g was comparable to that of their 
respective imino carbon methylated derivatives 4f and 4h (Figures 4, 5 B). Increased toxicity 
of the imino methylated derivatives in MDR cells was observed in some, but not all 
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investigated cell line pairs (see Table 1, Figure S9 for more details). Extending the analysis to 
molecules without available MMPs showed that the activity of the imino carbon methylated 
picolinylidene compounds surpasses that of the unsubstituted derivatives (Figure 5 C). 
Together with the pairwise comparisons, these data suggest that methylation of the imino 
carbon may influence the toxicity of NNS donor atom chelators. In contrast, the three 
investigated MMPs with ONS donor atom sets did not show sensitivity to imino carbon 
methylation (see Figure S10).  
 
2.7. Structure activity relationships  
Even though the designed library did not provide new P-gp-dependent MDR-selective 
compounds, a systematic comparison of the cytotoxicity data allowed some conclusions 
concerning structure activity relationships as summarized in the structure activity matrix 
(SARM) shown in Figure 6 [69]. Our approach to combine chemical entities of the parent 
compounds shown in Figure 2 (box VII) mostly yielded compounds with modest cytotoxicity. 
Dimerization of the thiosemicarbazid moiety of 1a, as present in compound 7a did not show 
activity below 50 µM. Combination of the thiosemicarbazone with the benzothiazole 
compound class resulted in compound 7b, which was not cytotoxic at concentrations up to 
50 µM. Combining the benzothiazole with the isatin part of 1a resulted in compound 7c, 
which also lacked toxicity. Finally, combination of isatin with the arylhydrazone moiety 
produced a nontoxic compound (7d).  
Comparison of the corresponding columns in the SARM shows that substitution of the phenyl 
moiety of TSCs results in lower toxicity of the N4-para-nitrophenyl derivatives as compared 
to para-tolyl and para-methoxyphenyl substituted counterparts (Figure 6, 1d vs. 1a, 1c; 2j vs. 
2f; 2k vs. 2e). 
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Hydrazinobenzothiazoles have been suggested to be superior to TSCs due to higher metabolic 
stability with retained pharmacologic activity [54]. Comparison of the corresponding columns 
in the SARM confirms the retained activity of the two scaffolds: the salicylidene-
hydrazinobenzothiazole 6a shows a similar toxicity than the corresponding TSC 3a. Likewise, 
the picolinylidene-hydrazinobenzothiazole 5a is comparable to the corresponding TSC 2a.  
 
2.8. Toxicity of hydrazino-benzothiazoles in MES-SA and MES-SA/Dx5 cells 
Further derivatives of the benzothiazole class (see Figure 2, boxes V and VI) were 
investigated to evaluate the effect of substituents in para position to the chelating phenolic 
OH, which is predicted to influence the stability of formed metal complexes. The biological 
results of the hydrazinobenzothiazole series are summarized in Figure 7. In the methoxy-
derivative of the salicylidene hydrazinobenzothiazole 6a (6g) the ability to chelate is 
hindered, as one of the three donor atoms is occupied by the methyl group. Theoretically, this 
compound could bind metals via a bidentate chelation mode, but for steric reasons the 
expected complex stability would be rather low. Lack of toxicity of 6g evidences the 
importance of chelation in the mechanism of toxicity. Introduction of an electron-donating 
methyl group (6e) or methoxy group (6c and 6d) in para position to the metal binding 
hydroxyl group decreases the toxicity of the compounds. In contrast, the strong electron-
withdrawing nitro group introduced at the same position increases toxicity (6f). In the case of 
the benzothiazoles there is a strong correlation of toxicity in both cell lines to the strongest 
calculated pKb value, which is known to influence the metal binding ability of the ligand (r² 
values 0.81 and 0.64 for MES-SA and MES-SA/Dx5 cells, respectively). Correlation with 
other chemical properties was not significant (Table S8). It is striking, that within this 
compound set the picolinylidene derivatives show an increased toxicity (box V, compounds 
5a-c) over salicylidene derivatives (box VI, compounds 6a-g). 
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2.9. Influence of different donor atoms on chelator toxicity  
Comparison of the rows within the SAR matrix offers an insight into the impact of different 
donor atom sets and the imino carbon substitution on toxicity of the compounds (Figure 6). In 
agreement with the observation on hydrazinobenzothiazoles, also the investigated salicylidene 
TSCs proved to be less toxic than their corresponding picolinylidene counterparts. Analysis of 
the matched molecular pairs (MMP) of ONS and NNS donors reveals a significant difference 
in toxicity across all investigated cell lines (Figure 8A). An extended analysis including 
compounds beyond the MMPs shown in Figure 8A confirms that chelators with an NNS or 
NNN donor set are significantly more toxic than the ONS chelators (Figure 5B, C). The pIC50 
values measured in the sensitive and resistant cells are overall rather similar, confirming the 
lack of P-gp influence on the toxicity of these compounds (Figure 5C and S8).  
Apart from the donor atoms alone, also steric factors will affect the ligands’ ability to chelate 
a metal ion. The impact of these steric and electronic effects on the biological activity is 
evident from the comparison of the two investigated aniline derivatives 2p and 5d to their 
picolinylidene derivatives 2c and 5b (see SARM, Figure 6): the latter show a greater toxic 
potential. 
 
2.10. Influence of donor atoms on drug activity patterns in the DTP database 
In order to investigate whether the apparent difference in the toxicity of ONS and NNS donor 
chelators was restricted to compounds studied here, we performed substructure searches 
within the DTP database that contains the publically available toxicity profile of 40,000 
compounds (Figures 9A, B and S9). Among the 1335 analogs identified in the DTP database 
(Figure S12), we found three MMPs with toxicity data on 60 cell lines (Figure 9C). Similarly 
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to the compounds investigated in the designed library, the 3 NNS chelators identified in the 
DTP set exhibited a higher toxic potential across the NCI-60 cell line panel than their 
respective ONS counterparts. Interestingly, the structurally related NSC95678, which is able 
to chelate in either binding mode, has a moderate toxicity between that of NNS and ONS 
chelators. Superior toxicity of the NNS donor set could also be observed on a larger set of 
NNS and ONS donor chelators but not in the subset of analogs that are not able to chelate 
metal ions (Figure 9D). Despite structural similarity, these compounds are unable to chelate 
because the putative donor atoms are either incorporated into ring systems or are otherwise 
occupied by substituents (examples are given in Figure S12). In this subset the toxicity of 
ONS and NNS compounds is similar, both being significantly less toxic than the chelators 
(Figure 9D). 
 
 
 
3. Discussion 
Chelators are widely investigated because of their therapeutic potential in the treatment of 
metal overload and diseases related to imbalanced metal homeostasis including 
hemochromatosis, β-thalassemia, Alzheimer’s or Parkinson’s diseases and cancer [8,9,12,70]. 
Several chelators display significant antitumor activity, and some were even shown to exhibit 
enhanced toxicity towards otherwise multidrug resistant cancer cell lines [13,15,21,40,43]. 
Increased sensitivity of MDR cancer cells suggested that P-glycoprotein may be an Achilles 
heel that can be targeted by MDR-selective compounds [15,39,40,43]. Our aim was to explore 
the chemical space around chelator classes such as the MDR selective isatin-β-thiosemi-
carbazone 1a or the P-gp-substrate pyridinyl TSC Triapine. A focused library was designed, 
allowing the systematic evaluation of different chelator scaffolds associated with MDR-
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selective toxicity or multidrug resistance. Para substituted aromatic moieties that were 
identified to be associated with MDR selective toxicity in isatin-β-thiosemicarbazone 
structures were attached to picolinylidene thiosemicarbazones (Figures 1, 2, box II). To 
further increase the similarity to the lead structure 1a, the ONS donor atom set was retained in 
the salicylidene thiosemicarbazones (Figures 1, 2; box III). Finally, a series of 
hydrazinobenzothiazoles derivatives (Figures 1,2; boxes V, VI) were compared to respective 
TSCs analogs.  
To evaluate the effect of P-gp on the compounds’ activity (i.e. resistance or collateral 
sensitivity), we characterized the toxicity of the compounds in a panel of drug sensitive and 
MDR cell lines. In agreement with literature data, we find that Triapine is subject to MDR 
[20,21,48], while the isatin-β-TSCs around 1a show MDR-selective activity [15,21,40,43,44]. 
While most of the compounds studied here show comparable toxic potency in the investigated 
cell lines, some clearly target MDR cells (Tables 1, S2 - S6, Figures S2 - S6, S8, S10). In case 
of picolinylidene N4-tolyl thiosemicarbazones 2i, 2h and 2g, the highest selectivity was 
achieved for the para-tolyl derivative 2g in MES-SA/Dx5 vs. MES-SA cells. This is in 
agreement with studies on isatin-β-TSCs, in which substituents in the para position of the N4-
phenyl were shown to improve MDR-selective toxicity [39,44]. Cell line specific effects, that 
were independent of P-gp function, were observed for the picolinylidene TSC 2c, the 
salicylidene TSC 3a, the arylhydrazones 4c and 4b, the picolinylidene benzothiazoles 5b and 
5a, as well as the salicylidene benzothiazoles 6a and 6b (Table 1). In case of the 
picolinylidene derivatives, compounds containing a methyl group at the imino carbon (2c, 2g, 
4b, 5b) show high selectivity ratios. The development of the MDR phenotype is a 
multifactorial process, and cell lines selected in toxins deploy several distinct mechanisms in 
addition to the overexpression of efflux pumps such as P-gp. Our earlier studies have clearly 
demonstrated that the activity of P-gp can sensitize MDR cells. The toxicity of MDR-
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selective compounds such as 1a is increased in a wide range of P-gp-expressing cells, and is 
abrogated by the downregulation or chemical inhibition of P-gp (Figure 3) [15,21,40,43]. Our 
results confirm that multidrug-resistant cells exhibit collateral sensitivity to selected 
compounds. However, in contrast to the isatin-β-thiosemicarbazones (1a-e), the selective 
toxicity of the newly investigated compounds (2c, 3a, 4c, 4b, 5b, 5a, 6a, 6b) was not 
influenced by the P-gp inhibitor Tariquidar (TQ), suggesting that the observed 
hypersensitivity of the MDR cells cannot be exclusively linked to the activity of P-gp, and 
should be rather explained by off-target effects linked to other specific resistance mechanisms 
or the genetic drift of the selected cells [39,71,72]. In a similar manner, enhanced toxicity of 
the N-(2-mercaptopropionyl)glycine tiopronin against a subset of (but not all investigated) 
MDR cell lines expressing P-gp was explained by the inhibition of glutathionperoxidase 
(GPx) [73,74]. Another example is the natural product Austocystin D, which possesses 
increased toxicity against some MDR cell lines as a result of increased activation by 
cytochrome P450 [75]. Increased sensitivity of MDR cells to the antimetabolite 2-deoxy-d-
glucose, the electron transport chain inhibitors rotenone and antimycin A [71,76,77] as well as 
certain P-gp-substrates [72,78–80] were explained by the ATP depleting effect of the 
transporter. According to this model, increased glycolysis compensates for the higher energy 
demand created by the “futile cycling” of the transporter [79,81,82], but the oxidative stress 
associated with oxidative phosphorylation ultimately results in the selective apoptosis of 
MDR cells [83]. ROS have not only been implicated in the paradoxical sensitivity of resistant 
cells, but also in the mechanism of toxicity of chelators [8,12,13].  
Since the mechanism of action and therefore the target of MDR selective compounds is not 
known, there is no clear understanding of their structure-activity relationships.  
Some of the compounds shown in Figure 2 have been reported earlier to show activity in 
diverse biological settings. In fact, compound classes III (3a-g) and VI (6a-f) are formed by 2-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Hydroxy-phenylhydrazones, which are described as pan assay interference compounds 
(PAINs) [65,66]. In a wide range of target-based assays, covering ion channels, enzymes, and 
protein-protein-interactions, this substructure has been reported to be problematic due to its 
reactivity, spectroscopic properties and the ability to form metal complexes as well as 
aggregates [65,66]. Redox active compounds might interfere with proteins, and by 
inactivating the target often lead to false positive results in target-directed drug discovery 
projects [66]. However, the same reactive, photosensitive, and redox-active compounds may 
be particularly suited for therapeutic uses in the areas of oncology, microbiology, and 
parasitology [65]. Here we use a phenotypic drug discovery (PDD) strategy [84,85] where we 
have no a priori assumption of the availability or activity of a particular molecular target 
and/or signaling pathway. PAINs may be also problematic because of possible interferences 
with several applied assays. Here assay dependent artefacts were excluded by using two 
complementary viability assays (Figure S2). In many cases not only free ligands, but also 
their metal complexes possess biological activity: picolinylidene TSC derivatives or their 
metal complexes have been reported to possess antimalarial [68], modest antibacterial [86], 
modest (to no) antifungal [87,88], but promising antitumor activity [88–90]. Salicylidene 
TSCs form redox-active complexes with various metal ions, including Ru(II) [91,92] and 
Cu(II) [93–95]. The free ligands and their Ni(II) [96], Cu(II), Ru(II) and Zn(II) [92,94,95] 
complexes were reported to possess antibacterial and antifungal activity. N4-phenyl-
salicylidene TSC (3a) has also been reported to show antitumor activity [95,97], GABAA 
receptor inhibition [98] and a very weak inhibition of RR [99]. Similarly, the acetaniline TSC 
(2p) forms Cu(II) complexes with moderate antibacterial and antifungal activity [46]. Similar 
to TSCs, benzothiazoles are also able to form biologically active metal complexes and find 
application as antibacterial and antifungal [45,46,100–102], as well as antitumor agents 
[45,49,50,54,103,104].  
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Compound 6g, the non-chelating derivative of the salicylidene hydrazinobenzothiazole 6a 
lacks toxic activity. The DTP database contains the activity patterns of standard anticancer 
drugs and tens of thousands of candidate anticancer agents [41,42]. In a subset of compounds 
identified by the substructure search in the DTP the putative donor atoms are occupied or 
incorporated in ring systems. These compounds lacked toxicity, corroborating the essential 
requirement of chelation. Interestingly, within this non-chelating subset, four compounds 
show an outstandingly high toxicity. Even though they contain the substructure motive by 
which they were identified, their structure is very different from the other compounds: They 
are derivatives of the marine natural product Trabectedin (ecteinascidin-743, Figure S12 D), 
which is currently undergoing clinical trials (phase III) in the USA, while it is approved for 
cancer treatment in Europe [105–107].  
In the designed library we observed a superior activity of NNS (and NNN) chelators over 
ONS chelators. According to the principle of hard and soft acids and bases (HSAB), chelators 
with distinct donor atoms will show a binding preference for different metal ions, and 
stabilize different oxidation states of these ions [108,109]. The investigated TSCs and 
hydrazinobenzothiazoles share a sulfur atom as a soft electron donor and a hydrazinic 
nitrogen as a hard donor. In the picolinylidene derivatives, the third Lewis base is the 
borderline pyridine nitrogen donor, while in the salicylidene derivatives the third donor atom 
is a hard Lewis base [108–110]. Therefore the salicylidene compounds might prefer harder 
metals than the picolinylidene derivatives [110]. A study comparing the stability of several 
metal complexes formed by the N4 unsubstituted salicyl- and pyridyl-carbaldehyde TSCs 
supports this general trend [111]. The different chelators might not only influence the stability 
of complexes formed with diverse metal ions, but also their redox properties. For example, 
ONS donors prefer higher oxidation states of iron and copper as compared to NNS donors. 
The primary mechanism of action of hard donor atom containing chelators may involve the 
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depletion of iron ions (exploited in iron overload disease), while soft donor atom chelators are 
more capable of enhancing the production of ROS upon complexation with iron [112,113]. 
Our conclusions were drawn based on a set of investigated TSCs and related hydrazino-
benzothiazoles, but a different behaviour is possible for unrelated compound classes. Hall et 
al. compared the anticancer potential of picolinylidene hydrazinobenzothiazole 5b with the 
corresponding benzoxazolyl derivative on a panel of 17 cancer cell lines. Both compounds, as 
well as their benzimidazolyl derivative, showed general antitumor activity in the nanomolar 
concentration range [54]. Sensitivity towards the NNS (NNN) or NNO (NNN) donor 
chelators was comparable in general, differences were rather small [54]. Yet, it might be 
possible, that in both cases, similarly to the reported salicylidene and acetaniline 
benzothiazoles, the benzothiazole moiety binds to the metal ion with the nitrogen rather than 
the sulfur [46,100,102]. 
Interestingly, superior activity of NNS over ONS chelators was also evident in the toxicity 
patterns within the DTP database. The analogs identified by the substructure search 
demonstrate high diversity that is presumably associated with distinct mechanisms of toxicity. 
In addition to free ligands, also complexes formed with diverse metal ions and NNS or ONS 
chelators were identified by the search in the database (Figures 9 and S9). It is important to 
note that the toxicity of the complexes is also dependent on the nature of the metal ions that 
are incorporated into the structure. Despite the structural diversity and the presence of metals, 
we find that the chelating donor atom set is a strong determinant of toxicity, as in the diverse 
set the NNS donor chelators show an increased toxic activity over the ONS donor chelators. 
Preferential toxicity associated with the NNS signature is no longer observed when the ability 
to form complexes is lost, as seen in the case of compounds in which the donor atoms are 
either incorporated into ring systems or are otherwise occupied by substituents. Comparing 
the two investigated aniline derivatives 2p and 5d with their picolinylidene derivatives 2c and 
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5b, we found that the latter show a greater toxic potential. This observation might be 
explained by a combination of steric and electronic reasons influencing the complexation of 
metal ions. Additionally, this result shows that donor atoms alone are not the sole 
determinants of toxicity. As a further moiety for the fine-tuning of biological activity, the 
imino carbon of the Schiff bases has been suggested since substitution at this position was 
reported to affect the toxicity of several Schiff base chelators [13,51,52]. A subset of NNS 
chelators became more toxic upon methylation at the imino carbon. One out of three MMPs 
from the NNN chelator pairs showed a similar behavior. Comparison of measured data of 
compounds with and without matched pairs suggested a beneficial effect of methylation in 
case of NNS donor chelators (Figures 5D). In contrast, toxicity was not influenced by imino 
carbon methylation for the investigated ONS donor chelators (Figure S10). 
The same trends could be observed in a larger set of DTP compounds. By separating 
molecules with unsubstituted and methylated imino carbons in the analysis of the NNS and 
ONS compounds identified in the DTP database, we found no significant influence of imino 
carbon methylation on the activity of ONS donors, while there was a tendency of higher 
toxicity among NNS donors with imino carbon methylation (Figure S13). However, our data 
does not allow a general conclusion regarding the role of imino carbon methylation in 
toxicity. 
 
4. Conclusions 
We synthesized a library around chelator scaffolds possessing variable activity against MDR 
cell lines. While some of the newly investigated compounds show enhanced toxicity in MDR 
cells, detailed analysis indicate that the library does contain bona fide MDR-selective 
compounds, whose toxicity would be directly enhanced by P-glycoprotein. We find that NNS 
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and NNN donor chelators show superior toxicity as compared to ONS derivatives regardless 
of the resistance status of the investigated cell lines. 
 
5. Experimental Section 
5.1. Materials and Methods 
Chemicals used for synthesis were procured from Acros Organics (Geel, Belgium), Alfa 
Aesar (Karlsruhe, Germany), Sigma-Aldrich (Schnelldorf, Germany) or TCI (Eschborn, 
Germany) and used without further purification. Column chromatography was performed 
using Silica gel 60 (40-63 µm, Merck, Darmstadt, Germany) as stationary phase. 1H NMR 
and 13C NMR spectra were obtained on a Bruker Advance 500 spectrometer or on a Varian 
INOVA 400 MHz spectrometer, respectively. DMSO-d6 or CDCl3 were used as solvents. 
Standard pulse programs were applied. Chemical shifts are expressed in ppm values using the 
residual solvent peaks as internal standards (DMSO-d6 2.50; 39.52 ppm or CDCl3 7.26; 77.16 
ppm) [114]. Elemental analyses of the final products were performed on a Vario EL elemental 
analyser (Hanau, Germany). The values for carbon, nitrogen and hydrogen are given in 
percentage. Purity of compounds, of which the elemental analysis did not fit, were confirmed 
to be ≥ 95% by HPLC-MS using a Perkin Elmer Series 200 micro LC system consisting of 
binary pumps, autosampler and UV/vis detector. A Kinetex XB C18 column *2.6 µm, 
150x4.6 mm, 100 A was used for separation the samples. Gradient elution was used with 
solvent A: 0.1% formic acid in water and B: 0.1% formic acid in acetonitrile. The flow rate 
was 600 µl/min and 10 µl of samples were injected. The UV chromatogram was recorded at 
254 nm. Mass spectrometric measurements were carried out on an AB Sciex 3200Q Trap 
tandem mass spectrometer equipped with Turbo V ion source. The instrument was scanned in 
Q1 mode in the range of 50-600 Da.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Commercially available derivatives of interest were obtained from DTP (NSC291330 (2b), 
NSC670963 (2d), NSC289100, NSC668332 (2h), NSC668336 (2i)), asinex 
(asx_BAS_00069712 (6f)), enamine (ena_T0512-7089 (2n), ena_T5848162 (4g), 
ena_T6047476 (6d), ena_T6242988 (4h)), IBS (ibs_STOCK2S-70644 (1e), ibs_STOCK3S-
52757 (6g), ibs_STOCK4S-04301 (6e)), Kemiome (kem_KOME-0110497 (2a)), Maybridge 
(mbr_JFD_01295 (4e), mbr_RDR_00069 (2l)), Otava (ota_7210500057 (3a)), Specs 
(spc_AB-337/13036073 (4d), spc_AN-329/40239015 (3d)), UkrOrg (uko_PB-00249083 (2o), 
uko_PB-01068874 (2m), uko_PB-05694495 (3g), uko_PB-05734828 (3e), uko_PB-
05735012 (3f), uko_PB-06424414 (4f), uko_PB-90126051 (6c)). 
Tariquidar was a kind gift from Dr. Susan Bates (NCI). 
 
5.2. Compound Synthesis 
General method: The Schiff bases were obtained by adding an ethanolic solution of the 
hydrazinyl component to the solution of the keto component in equimolar amounts, refluxing 
the mixture in the presence of catalytic amounts of acid. If not indicated otherwise, 
purification was carried out by recrystallization. Carbazides were prepared by adding an 
equimolar amount of hydrazine to the methanolic solution of the respective isothiocyanate 
[53]. For the picolinylidene derivatives with ethyl group in 5-position of the pyridine moiety 
(2e, 2k), 5-Ethylpicolinaldehyde was prepared from 5-ethyl-2-methyl-pyridine as reported 
previously [13,115]. 1H NMR (500 MHz, CDCl3): δ = 10.03 (s, 1H), 8.60 (d, 1H, 4J(H,H) = 
1.9 Hz,), 7.87 (d, 1H, 3J(H,H) = 8.0 Hz), 7.70 – 7.63 (m, 1H), 2.73 (q, 2H, 3J(H,H) = 7.6 Hz), 
1.28 (t, 3H, 3J(H,H) = 7.6 Hz). 13C NMR (500 MHz, CDCl3): δ = 193.3, 151.1, 150.2, 144.7, 
136.3, 121.7, 26.4, 15.0. 
 
5.2.1. Preparation of Carbazides: 
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5.2.1.1. N-(4-methoxyphenyl)hydrazinecarbothioamide (C-1) 
The reaction of 4-methoxyphenylisothiocyanate (1.000 g, 6.052 mmol) with hydrazine 
(0.37 mL 80% aqueous, 6.052 mmol) resulted in white crystals of the product in 97.4% yield 
(1.163 g, 5.90 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 9.51 (s, 1H), 8.94 (s, 1H), 7.44 (d, 
2H, 3J(H,H) = 8.2 Hz), 6.88 – 6.83 (m, 2H), 4.70 (s, 2H), 3.74 (s, 3H). 13C-NMR (126 MHz, 
DMSO-d6): δ = 179.8, 156.1, 132.2, 125.5, 113.2, 55.2. 
 
5.2.1.2. N-(4-tolyl)hydrazinecarbothioamide (C-2) 
The reaction of 4-tolylisothiocyanate (500 mg, 3.35 mmol) with hydrazine (0.20 mL 80% 
aqueous, 3.35 mmol) resulted in white needles of the product in 97.8% yield (594 mg, 
3.27 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 9.55 (s, 1H), 9.00 (s, 1H), 7.49 (d, 2H, 
3J(H,H) = 7.2 Hz), 7.10 (d, 2H, 3J(H,H) = 8.2 Hz), 4.74 (s, 2H), 2.27 (s, 3H). 13C-NMR (126 
MHz, DMSO-d6): δ = 179.5, 136.6, 133.1, 128.5 (2C), 123.5 (2C), 20.4. 
 
5.2.2.3. N-(4-nitrophenyl)hydrazinecarbothioamide (C-3) 
The reaction of 4-nitrophenylisothiocyanate (1.000 g, 5.56 mmol) with hydrazine (0.34 mL 
80% aqueous, 5.56 mmol), was carried out in a mixture of toluene and methanol, due to the 
low solubility of the starting material and resulted in ochre product crystals in 92.8% yield 
(1.095 g, 5.16 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 9.55 (s, 1H), 8.14 (s, 4H), 7.83 (s, 
1H), 6.55 (bs, 2H). 13C-NMR (126 MHz, DMSO-d6): δ = 178.8, 145.7, 142.5, 123.8 (2C), 
122.0 (2C). 
 
5.2.3. Preparation of isatin-β-thiosemicarbazones (Figures 1, 2, box I): 
5.2.3.1. N-(4’-methoxyphenyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (1a) 
[44] 
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The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-methoxyphenyl)hydrazinecarbothio-
amide C-1 (197.26 mg, 1.0 mmol) in ethanolic solution under HCl-catalysis resulted in a 
yellow fluffy precipitate, which was identified as the product in 89 % yield (291 mg, 
0.89 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 12.75 (s, 1H), 11.22 (s, 1H), 10.70 (s, 1H), 
7.76 (d, 1H, 3J(H,H) = 7.6 Hz), 7.50 – 7.44 (m, 2H), 7.36 (td, 1H, 3J(H,H) = 7.7 Hz, 4J(H,H) 
= 1.3 Hz), 7.13 – 7.08 (m, 1H), 6.99 – 6.95 (m, 2H), 6.94 (d, 1H, 3J(H,H) = 7.9 Hz), 3.78 (s, 
3H). 13C-NMR (126 MHz, DMSO-d6): δ = 176.5, 162.6, 157.4, 142.4, 132.0, 131.28, 131.25, 
127.1, 122.3, 121.3 (2C), 119.9, 113.5 (2C), 111.0, 55.3. Anal. Calcd. for C16H14N4SO2: C: 
58.88; H: 4.32; N: 17.17. Found: C: 58.58; H: 4.349; N: 16.95. 
 
5.2.3.2. N-(4’-methoxyphenyl)-2-(2-oxo-5-(trifluoromethoxy)-indoline-3-ylidene)-
hydrazinecarbothioamide) (1b) 
The reaction of 5-trifluoromethoxyisatin (50 mg, 0.22 mmol) with N-(4-
methoxyphenyl)hydrazinecarbothioamide C-1 (43 mg, 0.22 mmol) in ethanolic solution under 
HCl-catalysis resulted in a yellow fluffy precipitate, which was identified as the product in 
70 % yield (65.7 mg, 0.16 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 12.60 (s, 1H), 11.36 
(s, 1H), 10.78 (s, 1H), 7.78 (s, 1H), 7.49 – 7.41 (m, 2H), 7.41 – 7.31 (m, 1H), 7.02 (d, 1H, 
3J(H,H) = 5.0 Hz), 7.01 – 6.95 (m, 2H), 3.78 (s, 3H). 13C-NMR (126 MHz, DMSO-d6): δ = 
176.6, 162.7, 157.5, 143.5, 141.2, 131.1, 130.9, 127.3 (2C), 124.0, 121.5, 120.7 (d {121.19, 
119.15}, 1J(C,F) = 255.7 Hz), 114.4 (2C), 113.6, 112.1, 55.3. Anal. Calcd. for 
C17H13N4SO3F3: C: 49.76; H: 3.19; N: 13.65. Found: C: 49.61; H: 3.477; N: 13.53.  
 
5.2.3.3. N-(4’-tolyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (1c) [44] 
The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-tolyl)hydrazinecarbothioamide C-2 
(181.26 mg, 1.0 mmol) in ethanolic solution under acetic acid catalysis resulted in a yellow 
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fluffy precipitate, which was identified as the product in 53 % yield (162.8 mg, 0.53 mmol). 
1H-NMR (500 MHz, DMSO-d6): δ = 12.78 (s, 1H), 11.22 (s, 1H), 10.71 (s, 1H), 7.78 (d, 1H, 
3J(H,H) = 7.5 Hz), 7.49 (d, 2H, 3J(H,H) = 8.3 Hz), 7.36 (td, 1H, 4J(H,H) = 1.2 Hz, 3J(H,H) = 
7.7 Hz), 7.22 (d, 2H, 3J(H,H) = 8.2 Hz), 7.10 (td, 1H, 4J(H,H) = 0.7 Hz, 3J(H,H) = 7.6 Hz), 
6.94 (d, 1H, 3J(H,H) = 7.8 Hz), 2.33 (s, 3H). 13C-NMR (126 MHz, DMSO-d6): δ = 176.3, 
162.6, 142.4, 135.9, 135.3, 132.1, 131.3, 128.8 (2C), 125.4 (2C), 122.3, 121.3, 119. 9, 111.0, 
20.6. Anal. Calcd. for C16H14N4SO: C: 61.92; H: 4.55; N: 18.05. Found: C: 62.4; H: 4.402; N: 
18.54. 
 
5.2.3.4. N-(4’-nitrophenyl)-2-(2-oxoindoline-3-ylidene)hydrazinecarbothioamide (1d) 
[44] 
The reaction of isatin (147.13 mg, 1.0 mmol) with N-(4-tolyl)hydrazinecarbothioamide C-3 
(212.23 mg, 1.0 mmol) in ethanolic solution under acetic acid catalysis resulted in an orange-
yellowish fluffy precipitate, which was identified as the product in 71 % yield (242 mg, 
0.71 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 13.01 (s, 1H), 11.28 (s, 1H), 11.10 (s, 1H), 
8.36 – 8.24 (m, 2H), 8.14 – 8.03 (m, 2H), 7.78 (d, 1H, 3J(H,H) = 7.4 Hz), 7.40 (td, 1H, 
4J(H,H) = 1.2 Hz, 3J(H,H) = 7.7 Hz), 7.13 (td, 1H, 4J(H,H) = 0.8 Hz, 3J(H,H) = 7.6 Hz), 6.96 
(d, 1H, 3J(H,H) = 7.8 Hz). 13C-NMR (126 MHz, DMSO-d6): δ = 176.0, 162.7, 144.6, 144.1, 
142.7, 133.27, 131.8, 124.6 (2C), 123.9 (2C), 122.4, 121.5, 119.6, 111.2. Anal. Calcd. for 
C15H11N5SO3: C: 52.78; H: 3.25; N: 20.52. Found: C: 53.24; H: 3.57; N: 20.9. 
 
5.2.4. Preparation of picolinylidene thiosemicarbazones (Figures 1, 2, box II): 
5.2.4.1. N-(4’-methoxyphenyl)-2-(1-(pyridin-2-yl)ethylidene)hydrazinecarbothioamide 
(2c) 
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The reaction of 1-(pyridin-2-yl)ethanone (0.15 mL, 1.325 mmol) with N-(4-tolyl)hydrazine-
carbothioamide C-2 (250 mg, 1.325 mmol) in ethanolic solution under acetic acid catalysis 
resulted in a white precipitate, which was recrystallized to afford the product in 62.9 % yield 
(250.6 mg, 0.83 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 10.54 (s, 1H), 10.07 (s, 1H), 
8.60 (ddd, 1H, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.9 Hz, 3J(H,H) = 4.7 Hz), 8.54 (d, 1H, 3J(H,H) = 
8.2 Hz), 7.84 – 7.75 (sm, 1H), 7.43 – 7.36 (sm, 3H), 6.97 – 6.91 (sm, 2H), 3.78 (s, 3H), 2.46 
(s, 3H). 13C-NMR (126 MHz, DMSO-d6): δ = 177.7, 157.2, 154.7, 49.0, 148.6, 136.5, 132.2, 
127.9 (2C), 124.2, 121.3, 113.5 (2C), 55.4, 12.50. Anal. Calcd. for C15H16N4SO: C: 59.98; H: 
5.37; N: 18.65. Found: C: 60.0; H: 5.3; N: 18.76. 
 
5.2.4.2. 2-((5-ethylpyridin-2-yl)methylene)-N-(4’-
methoxyphenyl)hydrazinecarbothioamide (2e) 
The reaction of 5-ethylpicolinaldehyde (200 mg, 1.48 mmol) with N-(4-methoxyphenyl)-
hydrazinecarbothioamide C-1 (291.9 mg, 1.48 mmol) in ethanolic solution under acetic acid 
catalysis resulted in white crystals, of product in 60 % yield (229 mg, 0.73 mmol). The 
product seemed to be thermo labile, since it decomposed upon a further recrystallization trial. 
1H-NMR (500 MHz, DMSO-d6): δ = 11.87 (s, 1H), 10.09 (s, 1H), 8.44 (dd, 1H, 5J(H,H) = 
0.5 Hz, 4J(H,H) = 1.9 Hz), 8.35 (d, 1H, 3J(H,H) = 8.2 Hz), 8.17 (s, 1H), 7.69 (dd, 1H, 4J(H,H) 
= 2.2 Hz, 3J(H,H) = 8.2 Hz), 7.43 – 7.37 (sm, 2H), 6.97 – 6.91 (sm, 2H), 3.77 (s, 3H), 2.65 (q, 
2H, 3J(H,H) = 7.6 Hz), 1.21 (t, 3H, 3J(H,H) = 7.6 Hz). 13C-NMR (126 MHz, DMSO-d6): δ = 
176.6, 157.0, 150.9, 148.7, 142.9, 139.8, 135.7, 131.8, 127.6 (2C), 120.2, 113.3 (2C), 55.2, 
25.2, 15.1. Purity was determined with HPLC-MS to be ≥ 95% (m/z calculated for [M]: 
314.41, found 315.2 for [M + H]+).  
 
5.2.4.3. 2-(pyridin-2-ylmethylene)-N-(4’-tolyl)hydrazinecarbothioamide (2f) 
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The reaction of pyridine-2-carbaldehyde (160.7 mg, 1.5 mmol) with N-(4-tolyl)hydrazine-
carbothioamide C-2 (271.9 mg, 1.5 mmol) in ethanolic solution under acetic acid catalysis 
resulted in a white fluffy precipitate, which was identified as the product in 82.5 % yield 
(334.5 mg, 1.237 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 11.95 (s, 1H), 10.15 (s, 1H), 
8.58 (ddd, 1H, 5J(H,H) = 1.0 Hz, 4J(H,H) = 1.7 Hz, 3J(H,H) = 4.9 Hz), 8.43 (d, 1H, 3J(H,H) = 
8.0 Hz), 8.19 (s, 1H), 7.84 (ddd, 1H, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.8 Hz, 3J(H,H) = 7.6 Hz), 
7.44 – 7.40 (m, 2H), 7.39 (ddd, 1H, 3J(H,H) = 1.2 Hz, 3J(H,H) = 4.9 Hz, 3J(H,H) = 7.5 Hz), 
7.18 (d, 2H, 3J(H,H) = 8.0 Hz), 2.32 (s, 3H). 13C-NMR (126 MHz, DMSO-d6): δ = 176.5, 
153.3, 149.4, 143.0, 136.5, 136.5, 134.7, 128.6 (2C), 126.0 (2C), 124.2, 120.6, 20.7. Anal. 
Calcd. for C14H14N4S: C: 62.2; H: 5.22; N: 20.72. Found: C: 62.36; H: 5.228; N: 20.93.  
 
5.2.4.4. 2-(1-(pyridin-2-yl)ethylidene)-N-(4’-tolyl)hydrazinecarbothioamide) (2g) 
The reaction of 1-(pyridin-2-yl)ethanone (0.17 mL, 1.5 mmol) with N-(4-tolyl)hydrazine-
carbothioamide C-2 (271.9 mg, 1.5 mmol) in ethanolic solution under acetic acid catalysis 
resulted in white crystals, which were recrystallized from a CHCl3:EtOH mixture (1.5:1) to 
afford the product in 40.8 % yield (174 mg, 0.61 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 
10.58 (s, 1H), 10.10 (s, 1H), 8.60 (ddd, 1H, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.7, 3J(H,H) = 
4.7 Hz), 8.52 (d, 1H, 3J(H,H) = 8.2 Hz), 7.81 (ddd, 1H, 5J(H,H) = 1.9 Hz, 5J(H,H) = 7.4 Hz, 
5J(H,H) = 8.2 Hz), 7.45 – 7.37 (m, 3H), 7.18 (d, 2H, 3J(H,H) = 7.9 Hz), 2.46 (s, 3H), 2.32 (s, 
3H). 13C-NMR (126 MHz, DMSO-d6): δ = 177.3, 154.5, 149.0, 148.4, 136.5, 136.3, 134.7, 
128.5 (2C), 125.9 (2C), 124.0, 121.2, 20.6, 12.4. Anal. Calcd. for C15H16N4S: C: 63.35; H: 
5.67; N: 19.70. Found: C: 62.92; H: 5.602; N: 19.81.  
 
5.2.4.5. 2-(pyridin-2-ylmethylene)-N-(4-nitrophenyl)hydrazinecarbothioamide (2j) 
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The reaction of picolin aldehyde (160.7 mg, 1. 5 mmol) with N-(4-nitrophenyl)hydrazine-
carbothioamide C-3 (318.3 mg, 1.5 mmol) in ethanolic solution under acetic acid catalysis 
resulted in a bright yellow fluffy precipitate, which was recrystallized to afford the product in 
97 % yield (437 mg, 1.45 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 12.34 (s, 1H), 10.53 
(s, 1H), 8.61 (ddd, 1H, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.6 Hz, 3J(H,H) = 4.8 Hz), 8.41 (d, 1H, 
3J(H,H) = 8.0 Hz), 8.28 – 8.23 (m, 3H), 8.08 – 8.03 (m, 2H), 7.89 (td, 1H, 4J(H,H) = 1.5 Hz, 
3J(H,H) = 7.7 Hz), 7.43 (ddd, 1H, 5J(H,H) = 1.1 Hz, 4J(H,H) = 4.9 Hz, 3J(H,H) = 7.5 Hz). 
13C-NMR (126 MHz, DMSO-d6): δ = 175.8, 152.8, 149.4, 145.2, 144.2, 143.6, 136.5, 124.7 
(2C), 124.5, 123.7 (2C), 120.7. Anal. Calcd. for C13H11N5SO2: C: 51.82; H: 3.68; N: 23.24. 
Found: C: 52.13; H: 3.679; N: 23.51.  
 
5.2.4.6. 2-((5-ethylpyridin-2-yl)methylene)-N-(4’-nitrophenyl)hydrazinecarbothioamide 
(2k) 
The reaction of 5-ethylpicolinaldehyde (202.74 mg, 1.5 mmol) with N-(4-nitrophenyl)-
hydrazinecarbothioamide C-3 (318.3 mg, 1.5 mmol) in ethanolic solution under acetic acid 
catalysis resulted in orange crystals, which delivered the pure product in 49 % yield (242 mg, 
0.74 mmol) after column chromatography and recrystallization. 1H-NMR (500 MHz, DMSO-
d6): δ = 12.21 (bs, 1H), 10.52 (bs, 1H), 8.47 (d, 1H, 4J(H,H) = 1.6 Hz), 8.32 (d, 1H, 3J(H,H) = 
7.9 Hz), 8.27 – 8.24 (sm, 2H), 8.23 (s, 1H), 8.07 – 8.03 (sm, 2H), 7.74 (dd, 1H,4J(H,H) = 
2.0 Hz, 3J(H,H) = 8.4 Hz), 2.67 (q, 2H, 3J(H,H) = 7.6 Hz), 1.22 (t, 3H, 3J(H,H) = 7.6 Hz). 13C-
NMR (126 MHz, DMSO-d6): δ = 175.7, 150.5, 148.9, 145.3, 144.4, 143.5, 140.2, 135.8, 
124.6, 123.7 (2C), 120.4 (2C), 25.3, 15.1. Anal. Calcd. for C15H15N5SO2×0.5 H2O: C: 53.24; 
H: 4.77; N: 20.70. Found: C: 53.44; H: 4.72; N: 20.75.  
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5.2.5. Preparation of the acetaniline thiosemicarbazone (1-(1-(2-aminophenyl)-
ethylidene)amino)-3-(4’-methoxyphenyl)thiourea (2p) 
The reaction of 2-aceto-aniline (0.11 mL, 1.27 mmol) with 2-hydrazinobenzothiazole 
(250 mg, 1.27 mmol) in ethanolic solution under acetic acid catalysis delivered the product as 
a bright yellow solid in < 9.5 % yield (38 mg, 0.121 mmol) after column chromatography 
(PE:EE 4:1) and recrystallization. 1H-NMR (500 MHz, DMSO-d6): δ = 10.44 (s, 1H), 9.69 (s, 
1H), 7.46 (d, 2H, 3J(H,H) = 9.1 Hz), 7.36 (dd, 1H, 4J(H,H) = 1.4 Hz, 3J(H,H) = 8.0 Hz), 7.06 
– 7.01 (sm, 1H), 6.92 – 6.88 (m, 2H), 6.71 (dd, 1H, 4J(H,H) = 1.1 Hz, 3J(H,H) = 8.0 Hz), 6.57 
– 6.52 (sm, 1H), 3.75 (s, 3H), 2.32 (s, 3H) – NH2 not visible. The purity of this compound 
was estimated wotj HPLC-MS method to be between 75 and 85% (m/z calculated for [M]: 
314.41, found 315.2 for [M + H]+). 
 
5.2.6. Preparation of salicylidene thiosemicarbazones (Figures 1, 2, box III): 
5.2.6.1. 2-(2-hydroxybenzylidene)-N-(4’-methoxyphenyl)hydrazinecarbothioamide (3b) 
Salicylic aldehyde (0.135 mL, 1.267 mmol) was reacted with N-(4-
methoxyphenyl)hydrazinecarbothioamide C-1 (250 mg, 1.267 mmol) in ethanolic solution 
under acetic acid catalysis. The crude product was purified with column chromatography 
(PE:EE 4:1) and allowed to crystallize at -20°C. The product was obtained as white crystals in 
a yield of 61.8 % (236 mg, 0.78 mmol). 1H-NMR (500 MHz, CDCl3): δ = 10.92 (s, 1H), 8.55 
(s, 1H), 7.52 – 7.48 (sm, 2H), 7.37 – 7.31 (m, 2H), 7.29 (dd, 1H, 4J(H,H) = 1.6 Hz, 3J(H,H) = 
7.6 Hz), 7.04 (d, 1H, 3J(H,H) = 7.9 Hz), 6.95 (td, 1H, 4J(H,H) = 1.1 Hz, 3J(H,H) = 7.6 Hz), 
6.89 – 6.84 (sm, 2H), 3.79 (s, 3H) – OH not visible. 13C-NMR (126 MHz, CDCl3): δ = 158.9, 
158.8, 156.8, 150.0, 132.2, 131.8, 131.5, 122.4 (2C), 119.8, 118.3, 117.0, 114.4 (2C), 55.7. 
Anal. Calcd. for C15H15N3SO2: C: 59.78; H: 5.02; N: 13.94. Found: C: 59.75; H: 5.047; N: 
14.11. 
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5.2.6.2. 2-(2-hydroxybenzylidene)-N-(4’-tolyl)hydrazinecarbot hioamide (3c)  
The reaction of salicylic aldehyde (0.147 mL, 1.379 mmol) with N-(4-tolyl)hydrazinecarbo-
thioamide C-2 (250 mg, 1.267 mmol) in ethanolic solution under acetic acid catalysis resulted 
in yellowish crystals, which delivered the pure product in 34 % yield (133.8 mg, 0.47 mmol) 
after recrystallization. 1H-NMR (500 MHz, DMSO-d6): δ = 11.67 (s, 1H), 9.94 (s, 1H), 8.48 
(s, 1H), 8.04 (d, 1H, 3J(H,H) = 7.6 Hz), 7.45 – 7.39 (sm, 2H), 7.25 – 7.20 (sm, 1H), 7.15 (d, 
2H, 3J(H,H) = 8.1 Hz), 6.87 (dd, 1H, 4J(H,H) = 0.9 Hz, 3J(H,H) = 8.2 Hz), 6.82 (t, 1H, 
3J(H,H) = 7.5 Hz), 2.30 (s, 3H). 13C NMR (101 MHz, DMSO-d6): δ = 175.8, 156.5, 139.9, 
136.6, 134.3, 131.2, 128.5 (2C), 127.1, 125.6 (2C), 120.3, 119.2, 116.04, 20.6. Anal. Calcd. 
for C15H15N3SO: C: 63.13; H: 5.30; N: 14.73. Found: C: 63.12; H: 5.249; N: 14.89.  
 
5.2.7. Preparation of picolinylidene hydrazinobenzothiazoles (Figures 1, 2, box V): 
As a general comment on the hydrazinobenzothiazole derivatives from boxes V, VI and VII, 
in the 13C NMR spectra (especially measured by attached proton test (APT) method) some 
signals were not detectable. Mainly this occurred for the bridging quaternary carbons C-3’a 
and C-7’a, but dependent on the respective compounds also for some other signals. Those are 
indicated below. 
 
5.2.7.1. 2’-(2-(pyridin-2-yl)methylene)hydrazinyl)-1’,3’-benzothiazole (5a) 
The reaction of picolinaldehyde (0.144 mL, 1.513 mmol) with 2-hydrazinobenzothiazole 
(250 mg, 1.513 mmol) in ethanolic solution under acetic acid catalysis resulted in bright 
yellowish shining crystals, which delivered the pure product in 74.8 % yield (287.7 mg, 
1.132 mmol) after recrystallization. 1H-NMR (500 MHz, DMSO-d6): δ = 12.48 (bs, 1H), 8.60 
(ddd, 1H, 5J(H,H) = 1.0 Hz, 4J(H,H) = 1.7 Hz, 3J(H,H) = 5.0 Hz), 8.14 (s, 1H), 7.91 (d, 1H, 
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3J(H,H) = 7.9 Hz), 7.87 (m, 1H), 7.80 (d, 1H, 3J(H,H) = 7.9 Hz), 7.49 (d, 1H, 3J(H,H) = 
5.9 Hz), 7.38 (ddd, 1H, 4J(H,H) = 1.6 Hz, 3J(H,H) = 4.9 Hz, 3J(H,H) = 7.3 Hz), 7.35 – 7.29 
(sm, 1H), 7.17 – 7.10 (sm, 1H). 13C-NMR (101 MHz, DMSO-d6): δ = 167.1, 153.1, 149.5, 
136.8, 126.0, 123.9, 121.9, 121.6, 119.4. Signals for HC=N, C-3, C-3’a and C-7’a were not 
detectable. Anal. Calcd. for C13H10N4S: C: 61.4; H: 3.96; N: 22.03. Found: C: 61.81; H: 
3.936; N: 22.4. Purity was additionally determined with HPLC-MS to be ≥ 95% (m/z 
calculated for [M]: 254.31, found 255.2 for [M + H]+). 
 
5.2.7.2. 2’-(2-(1-(pyridin-2-yl)ethylidene)hydrazinyl)-1’,3’-benzothiazole (5b) 
The reaction of 1-(pyridin-2-yl)ethanone (0.17 mL, 1.513 mmol) with 2-
hydrazinobenzothiazole (250 mg, 1.513 mmol) in ethanolic solution under acetic acid 
catalysis resulted in beige precipitate, which delivered the pure product after recrystallization. 
The yield was not determined. NMRs revealed the presence of acetic acid in the cristals, 
therefore EA analysis was adapted accordingly.1H-NMR (500 MHz, DMSO-d6): δ = 11.86 
(bs, 1H), 8.59 (ddd, 1H, 5J(H,H) = 0.9 Hz, 4J(H,H) = 1.6 Hz, 3J(H,H) = 4.7 Hz), 8.08 (d, 1H, 
3J(H,H) = 8.2 Hz), 7.90 – 7.83 (sm, 1H), 7.74 (d, 1H, 3J(H,H) = 7.6 Hz), 7.41 – 7.36 (sm, 
2H), 7.33 – 7.27 (sm, 1H), 7.11 (td, 1H, 4J(H,H) = 0.9 Hz, 3J(H,H) = 7.8 Hz), 2.43 (s, 3H). 
13C-NMR (126 MHz, DMSO-d6): δ = 168.2, 155.1, 148.6, 136.4, 126.0, 123.5, 121.7, 121.7, 
119.7, 12.7 – the signals for CH3C=N, C-3, C-3‘a, C-7’a were not detectable. Anal. Calcd. for 
C14H12N4S×0.7 C2H4O2: C: 59.6; H: 4.8; N: 18.1. Found: C: 59.1; H: 4.9; N: 18.0. 
Additionally purity was determined with HPLC-MS to be ≥ 95% (m/z calculated for [M]: 
268.34, found 268.8 for [M + H]+, 291.3 for [M + Na]+). 
 
5.2.7.3. 2’-(2-(5-ethylpyridin-2-yl)methylene)hydrazinyl)-1’,3’-benzothiazole (5c) 
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The reaction of 5-ethyl-picolinaldehyde (200 mg, 1.48 mmol) with 2-hydrazinobenzothiazole 
(244.5 mg, 1.480 mmol) in ethanolic solution under acetic acid catalysis resulted in cream-
colored precipitate, which delivered the pure product in 46 % yield (192.2 mg, 0.681 mmol) 
after recrystallization. 1H-NMR (500 MHz, DMSO-d6): δ = 12.41 (bs, 1H), 8.46 (dd, 1H, 
5J(H,H) = 0.6 Hz, 4J(H,H) = 2.1 Hz), 8.13 (s, 1H), 7.84 (d, 1H, 3J(H,H) = 7.9 Hz), 7.79 (d, 
1H, 3J(H,H) = 7.9 Hz), 7.73 (ddd, 1H, 3J(H,H) = 0.5 Hz, 3J(H,H) = 2.1 Hz, 3J(H,H) = 8.2 Hz), 
7.48 (d, H, 3J(H,H) = 4.8 Hz), 7.31 (td, 1H, 3J(H,H) = 1.3 Hz, 3J(H,H) = 8.0 Hz), 7.17 – 7.10 
(sm, 1H), 2.66 (q, 2H, 3J(H,H) = 7.7 Hz), 1.21 (t, 3H, 3J(H,H) = 7.7 Hz). 13C-NMR (126 
MHz, DMSO-d6): 167.0, 150.8, 148.9, 139.4, 136.0, 126.0, 121.8, 121.5, 119.0, 25.2, 15.1 – 
the signals for HC=N, C-3, C-3’a, C-7’a were not visible. Anal. Calcd. for C15H14N4S: C: 
63.80; H: 5.00; N: 19.84. Found: C: 63.47; H: 4.886; N: 19.81.  
 
5.2.8. Preparation of the acetaniline hydrazinobenzothiazole 2-(1-(2-(1’,3’-benzothiazol-
2’-yl)hydrazine-1-ylidene)ethyl)aniline (5d): 
The reaction of 2-aceto-aniline (0.10 mL, 1.21 mmol) with 2-hydrazinobenzothiazole 
(200 mg, 1.21 mmol) in ethanolic solution under acetic acid catalysis delivered the product as 
a greyish brownish solid after recrystallization. 
1H-NMR (500 MHz, DMSO-d6): δ = 11.62 (s, 1H), 7.67 (d, 1H, 3J(H,H) = 7.9 Hz), 7.43 (dd, 
1H, 4J(H,H) = 1.4 Hz, 3J(H,H) = 8.0 Hz), 7.30 – 7.19 (m, 2H), 7.10 – 7.00 (m, 2H), 6.82 (s, 
2H), 6.76 (dd, 1H, 4J(H,H) = 1.3 Hz, 3J(H,H) = 8.2 Hz), 6.61 – 6.51 (sm, 1H), 2.43 (s, 3H). 
13C-NMR (126 MHz, DMSO-d6): δ = 165.3, 156.5, 147.4, 129.2, 129.0, 126.2, 121.9, 121.2, 
118.1, 116.0, 115.0, 114.1, 15.7. The signals for C-3’a and C-7’a were not detectable. Purity 
was determined with HPLC-MS to be ≥ 95% (m/z calculated for [M]: 282.36, found 283.1 for 
[M + H]+). 
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5.2.9. Preparation of salicylidene hydrazinobenzothiazoles (Figures 1, 2 box VI): 
5.2.9.1. 2-((2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)methyl)phenol (6a) 
The reaction of salicylic aldehyde (0.13 mL, 1.21 mmol) with 2-hydrazinobenzothiazole 
(200 mg, 1.21 mmol) in ethanolic solution under acetic acid catalysis delivered the pure 
product as a white precipitate in 93.3 % yield (306 mg, 1.13 mmol) after recrystallization. 1H-
NMR (500 MHz, DMSO-d6): δ = 12.14 (s, 1H), 10.44 (s, 1H), 8.45 (s, 1H), 7.74 (d, 1H, 
3J(H,H) = 7.9 Hz), 7.61 (d, 1H, 3J(H,H) = 6.6 Hz), 7.41 – 7.32 (m, 1H), 7.31 – 7.27 (sm, 1H), 
7.27 – 7.24 (sm, 1H), 7.09 (td, 1H, 4J(H,H) = 1.3 Hz, 3J(H,H) = 7.9 Hz),6.95 – 6.88 (m, 2H). 
13C-NMR (126 MHz, DMSO-d6): δ = 166.4, 156.6, 147.0, 130.8, 127.7, 126.2, 121.8, 121.5, 
119.6, 119.4, 116.1 – the signals for C-6’, C-3‘a and C-7’a were not visible. Anal. Calcd. for 
C14H11N3O: C: 62.43; H: 4.12; N: 15.60. Found: C: 62.56; H: 4.086; N: 15.76. Purity was 
additionally determined with HPLC-MS to be ≥ 95% (m/z calculated for [M]: 269.32, found 
315.2 for [M + H]+). 
 
5.2.9.2. 2-(1-(2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)ethyl)phenol (6b) 
The reaction of 2-hydroxyacetophenon (0.15 mL, 1.21 mmol) with 2-hydrazinobenzothiazole 
(200 mg, 1.21 mmol) in ethanolic solution under acetic acid catalysis delivered the pure 
product as a yellow precipitate in 92 % yield (315 mg, 1.11 mmol) after recrystallization. 1H-
NMR (500 MHz, DMSO-d6): δ = 12.52 (bs, 1H), 7.66 (d, 1H, 3J(H,H) = 7.7 Hz), 7.59 (dd, 
1H, 4J(H,H) = 1.0 Hz, 3J(H,H) = 7.8 Hz), 7.30 – 7.24 (m, 2H), 7.19 (d, 1H, 3J(H,H) = 7.8 Hz), 
7.06 (t, 1H, 3J(H,H) = 7.5 Hz), 6.93 – 6.87 (m, 2H), 6.50 (bs, 1H), 2.50 (s, 3H). 13C-NMR 
(126 MHz, DMSO-d6): δ = 165.1, 159.6, 158.2, 141.2, 130.6, 128.4, 126.7, 123.7, 122.5, 
121.6, 119.9, 118.7, 116.7, 112.4, 14.4. Anal. Calcd. for C15H13N3SO×1.25 H2O: C: 58.9; H: 
5.11; N: 13.74. Found: C: 58.7; H: 4.728; N: 13.85.  
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5.2.10. Preparation of combined structures (Figures 1, 2, box VII): 
5.2.10.1. N,N-bis(4-methoxyphenyl)hydrazine-1,2-bis(carbothioamide) (7a) 
The reaction of 4-methoxyphenylisothiocyanate (413.1 mg, 2.5 mmol) with hydrazine 
(0.06 mL 80% aqueous, 1.25 mmol) in ethanolic solution delivered the pure product as a 
white solid in 68.5 % yield (310 mg, 0.856 mmol) after recrystallization. 
1H-NMR (500 MHz, DMSO-d6): δ = 9.69 (s, 2H), 9.52 (s, 2H), 7.38 (d, 4H, 3J(H,H) = 
8.8 Hz), 6.93 – 6.86 (m, 4H), 3.75 (s, 6H). 13C-NMR (126 MHz, DMSO-d6): δ = 156.8 (2C), 
132.1 (2C), 126.8 (4C), 113.5 (4C), 55.35 (2C). – for the quaternary C=S no signal was 
visable in APT test, the signal at 126.8, which was assigned for C-2, C-2’, C-6 and C-6’ had a 
remarkably low intensity. Anal. Calcd. for C16H18N4S2O2: C: 53.02; H: 5.01; N: 15.46. Found: 
C: 53.18; H: 5.047; N: 15.66.  
 
5.2.10.2. 3-[(1’,3’-benzothiazol-2’yl)amino]-1-(4-methoxyphenyl)thiourea (7b) 
The reaction of N-(4-methoxyphenyl)hydrazinecarbothioamide C-1 (250 mg, 1.513 mmol) 
with 2-hydrazinobenzothiazole (250 mg, 1.513 mmol) in ethanolic solution delivered the pure 
product as a yellow solid in 75 % yield (357.2 mg, 1.139 mmol) after recrystallization. 
1H-NMR (500 MHz, DMSO-d6): δ = 13.38 (s, 1H), 7.66 (s, 1H), 7.60 (dd, 1H, 3J(H,H) = 
1.3 Hz, 3J(H,H) = 8.2 Hz), 7.37 – 7.31 (sm, 1H), 7.30 – 7.25 (sm, 2H), 7.19 (dd, 1H, 3J(H,H) 
= 1.4 Hz, 3J(H,H) = 7.7 Hz), 7.10 – 7.06 (sm, 2H), 6.93 (td, 1H, 3J(H,H) = 1.4 Hz, 3J(H,H) = 
7.7 Hz), 3.82 (s, 3H). For one NH no signal was visible. 13C-NMR (101 MHz, DMSO-d6): δ = 
165.7, 159.9, 148.4, 139.5, 133.5, 130.6, 129.7 (2C), 124.6, 124.5, 123.3, 119.6, 114.8 (2C), 
55.6. Anal. Calcd. for C15H14N4S2O: C: 54.52; H: 4.27; N: 16.96. Found: C: 54.26; H: 4.082; 
N: 16.7.  
 
5.2.10.3. 3-(2-(1’,3’-benzothiazol-2’-yl)hydrazine-1-ylidene)-2,3-dihydro-indol-2-one (7c) 
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The reaction of isatin (222.6 mg, 1.513 mmol) with 2-hydrazinobenzothiazole (250 mg, 
1.513 mmol) in ethanolic solution under acetic acid catalysis delivered the pure product as a 
yellow precipitate after recrystallization (The yield was not determined). 1H-NMR (500 MHz, 
DMSO-d6): δ = 13.38 (s, 1H), 11.24 (s, 1H), 7.94 (d, 1H, 3J(H,H) = 7.6 Hz), 7.67 (d, 1H, 
3J(H,H) = 7.6 Hz), 7.55 (d, 1H, 3J(H,H) = 7.3 Hz), 7.44 – 7.39 (sm, 1H), 7.39 – 7.34 (sm, 
1H), 7.30 – 7.25 (m, 1H), 7.10 (t, 1H, 3J(H,H) = 7.7 Hz), 6.97 (d, 1H, 3J(H,H) = 7.9 Hz). 13C-
NMR (126 MHz, DMSO-d6): δ = 141.6, 130.9, 126.4, 123.3, 122.4, 121.9, 120.5, 120.0, 
119.7, 111.1. Signals for C-3, C-3a’, and C-7a’ were not visible in the APT test. Purity of the 
compound was determined with HPLC-MS to be ≥ 95% (m/z calculated for [M]: 294.33, 
found 295.2 for [M + H]+). 
 
5.2.10.4. 3-(2’-(6’-methoxypyrimidin-4’-yl)hydrazono)inulin-2-one (7d) 
4-hydrazinyl-6-methoxypyrimidine necessary for the synthesis of 7d was prepared as 
described earlier in a two-step approach starting from 4,6-dichloropyrimidine.[13,115] 
1H NMR (500 MHz, CDCl3): δ = 8.26 (s, 1H), 6.42 (bs, 1H), 6.07 (s, 1H), 3.92 (s, 3H), 3.42 
(bs, 2H). 13C NMR (126 MHz, CDCl3): δ = 170.7, 167.2, 157.7, 84.9, 53.9. The product 
(150 mg, 1.04 mmol) was than reacted with isatin (152.7 mg, 1.04 mmol) in ethanolic 
solution under acetic acid catalysis. The reaction delivered the pure product as a yellow 
powder after column chromatography and recrystallization in 23.9 % yield (68 mg, 
0.248 mmol). 1H-NMR (500 MHz, DMSO-d6): δ = 11.09 (bs, 1H), 10.70 (s, 1H), 8.51 (s, 1H), 
8.11 (d, 1H, 3J(H,H) = 7.9 Hz), 7.35 (td, 1H, 4J(H,H) = 0.9 Hz, 3J(H,H) = 7.7 Hz), 7.04 (td, 
1H, 4J(H,H) = 0.9 Hz, 3J(H,H) = 7.6 Hz), 6.89 (d, 1H, 3J(H,H) = 7.9 Hz), 6.63 (s, 1H), 3.93 (s, 
3H). 13C-NMR (126 MHz, DMSO-d6): δ = 170.2, 164.6, 163.1, 158.2, 143.1, 135.8, 131.7, 
125.7, 121.5, 120.0, 110.9, 87.8, 53.9. Anal. Calcd. for C13H11N5O×H2O: C: 54.35; H: 4.56; 
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N: 24.38. Found: C: 54.85; H: 4.517; N: 23.26. Additionally purity was determined with 
HPLC-MS to be ≥ 95% (m/z calculated for [M]: 269.26, found 270.0 for [M + H]+). 
 
5.3. In Vitro testing 
5.3.1. Cell culture 
The human ovarian carcinoma cell lines A2780 and the doxorubicin selected multidrug 
resistant counterpart A2780adr were obtained from ECACC, UK, (A2780: No. 93112519, 
A2780adr: No. 93112520), and cultivated in RPMI (Sigma Aldrich, Germany) supplemented 
with 10% fetal bovine serum and 50 unit/mL penicillin and streptomycin (Sigma Aldrich, 
Germany). Human foreskin fibroblast (HFF) cells were obtained from ATCC. HFF cells were 
cultured in DMEM supplemented with 10% FCS and 50 unit/mL penicillin and streptomycin. 
The human uterine sarcoma cell lines MES-SA and the doxorubicin selected MES-SA/Dx5 
were obtained from ATCC (MES-SA: No. CRL-1976™, MES-SA/Dx5: No. CRL-1977™) 
and cultivated in DMEM (Sigma Aldrich, Hungary). The human cervix carcinoma cell line 
KB-3-1 and the vinblastine selected KB-V1 (kind gifts from Dr. Michael M. Gottesman, 
National Institutes of Health) were cultivated in DMEM. MES-SA and MES-SA/Dx5 cells 
expressing mCherry protein were engineered using a lentiviral system (Tóth et al., in 
preparation). The phenotype of the resistant cells was verified using cytotoxicity assays (not 
shown). DMEM media (Sigma Aldrich, Hungary) were supplemented with 10% fetal bovine 
serum, 5 mmol/L glutamine, and 50 unit/mL penicillin and streptomycin (Life Technologies). 
All cell lines were cultivated at 37 °C, 5% CO2. 
 
5.3.2. MTT viability assay 
MTT viability assays were performed as described earlier with minor modifications 
[13,27,116]. Briefly, cells were seeded into 96-well tissue culture plates (Sarstedt, Newton, 
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USA / Orange, Braine-l'Alleud, Belgium) in the appropriate density evaluated for each cell 
line (5000 cells per well for MES-SA/Dx5 and KB-3-1/V1 cells, 10000 cells per well for 
A2780 cells) and allowed to attach for 12 h. Test compounds were added to achieve the 
required final concentration in a final volume of 200 µL per well. After an incubation period 
of 72 h, the supernatant was removed and fresh medium supplemented with the MTT reagent 
(0.83 mg/mL) was added. Incubation with MTT at 37 °C was terminated after 1 h by 
removing the supernatants and lysing the cells with 100 µL DMSO per well. Viability of the 
cells was measured spectrophotometrically by absorbance at 540 nm using either a Perkin 
Elmer Victor X3, Perkin Elmer EnSpire, or a BMG POLARstar microplate reader. Data was 
background corrected by subtraction of the signal obtained from unstained cell lysates and 
normalized to untreated cells. Curves were fitted by Prism software [117] using the sigmoidal 
dose-response model (comparing variable and fixed slopes). Curve fit statistics were used to 
determine the concentration of test compound that resulted in 50% toxicity (IC50). 
 
5.3.3. Fluorescent assay using mCherry transfected MES-SA and MES-SA/Dx5 cells 
Cells were seeded either on 96 or 384 well plates (Greiner bio-one, Hungary), using a volume 
of 100 or 40 µL and a density of 5000 or 2500 cells per well and allowed to attach for 24 h. 
Dilutions of the test compounds were added to achieve the required final concentration in a 
final volume of 200 µL per well for 96, and 60 µL for 384 well plates. After a 72 h incubation 
period, fluorescence was measured using a PerkinElmer EnSpire Multimode Plate Reader at 
585nm excitation and 610 nm emission wavelengths. 
 
 
5.3.4. Calcein AM Assay 
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The activity of P-gp was quantified by the Calcein AM assay [67]. Briefly, cells were stained 
with Calcein AM (Life Technologies, USA) in the presence or absence of the P-gp-inhibitor, 
verapamil, and then measured with a FACSCanto flow cytometer (BD Biosciences, USA). 
Dead cells were separated by TO-PRO®-3 DNA dye staining (Life Technologies, USA). To 
evaluate the effect of the compounds on the functional expression of P-gp, MES-SA/Dx5 cells 
were cultured for five days in the presence of selected compounds at IC20 concentrations, as 
calculated from viability assays. Fresh medium was added without the drugs every fifth day to 
support recovery. Functional expression of P-gp was evaluated by the Calcein AM assay 
when the cells reached 80% confluency.  
 
5.3.5. Immunocytochemistry  
Cells were plated onto 8-well chambers (Nunc Lab-Tek II chamber slide system, Thermo 
Scientific). After 1 day, cells were fixed with 4% paraformaldehyde in Dulbecco’s modified 
phosphate-buffered saline (DPBS) for 15 min at room temperature. After three washing steps 
with DPBS, nonspecific antibody binding was blocked for 1 h at room temperature in DBS 
containing 2 mg/mL BSA, 1% fish gelatin, 5% goat serum, and 0.1% Triton-X 100. The 
samples were then incubated with anti-P-gp (monoclonal anti-human MRK16, Kamiya 
Biomedical) primary antibody in blocking solution at a 1:500 dilution for 1 h at room 
temperature. After washing with DPBS, the cells were incubated for 1 h with Phycoerithrin-
conjugated goat anti-mouse IgG (Invitrogen) secondary antibody in blocking solution at 1:250 
dilution at room temperature. Secondary antibodies were diluted in the blocking solution at 
1:250 in each case. Phycoerithrin-conjugated goat anti-mouse IgG antibody (Invitrogen) was 
applied to detect P-glycoprotein. DAPI (Invitrogen) was used for nuclear staining (1 µM, 
10 min long incubation in DPBS). The stained samples were examined by an Axioscope 2 
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fluorescent microscope (Zeiss, Thornwood, NY) and a Zeiss LSM 710 confocal laser 
scanning microscope. 
 
5.4. Analysis of DTP data 
Substructure searches for NNS and ONS chelators were performed on the DTP database using 
the Instant J Chem software package from Chemaxon [56]. The resulting compounds were 
visually inspected for presence of metal ions and the ability to chelate. Numbers of search 
results and compounds with available biodata are given in the supporting information (Figure 
S12). Results were refined by an additional substructure search distinguishing between imino 
methylated and desmethylated derivatives. Numbers of these refinements are given in Figure 
S13. For the general comparison of toxicity (Figures 9D, S9), the data on all 60 cell lines was 
averaged for each compound.  
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Captions for Schemes and Figures: 
Scheme 1. Synthesis of different Schiff bases starting from the preparation of 
thiosemicarbazides C-1 (R1: OCH3), C-2 (R1: CH3), C-3 (R1: NO2), or 2-hydrazino-
benzothiazole, respectively. Reaction conditions: a: MeOH, stirring at rt; b: EtOH, HCl or 
HOAc catalysis, refluxing. X = N for compound series 2 and 5; X = C-OH for compound 
series 3 and 6. Substituents are R1: CH3, OCH3 or NO2; R2: H, CH3, R3: H, OCF3. Further 
compounds listed in Figure 2 were commercially available and purchased to complement the 
library. 
 
Figure 1. Library design. The five molecules shown in the upper 3 panels possess variable 
MDR-selective toxicity and served as a starting point for the library design around isatin-β-
Thiosemicarbazones (TSC, box I), picolinylidene TSCs (box II), salicylidene TSCs (box III), 
arylhydrazones (box IV), picolinylidene hydrazinobenzothiazoles (box V), salicylidene 
hydrazinobenzothiazoles (box VI), as well as molecules with combined chemical entities (box 
VII). Chelators with ONS, NNS and NNN donor atoms are shown in red, blue and green 
boxes, respectively; donor atoms of example ligands are highlighted. 
 
Figure 2. Library design. Overview of synthesized and purchased picolinylidene TSCs 
(box II), the acetaniline TSC 2p, salicylidene TSCs (box III), arylhydrazones (box IV), 
picolinylidenehydrazinobenzothiazoles (box V), the acetaniline-hydrazinebenzothiazole 5d, 
salicylidene-hydrazinobenzothiazoles (box VI) and molecules with combined chemical 
entities (box VII). Chelators with ONS, NNS and NNN donor atoms are shown in red, blue 
and green boxes, respectively. 
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Figure 3. Confirmation of MDR selective activity of isatin-β-thiosemicarbazones. A-C: Dose 
response curves in absence (black) and presence (grey) of the P-gp inhibitor Tariquidar 
(1 µM), obtained from 2 to 4 independent experiments of MTT assays on MES-SA (open 
squares) and MES-SA/Dx5 (filled squares) cells for A: Triapine, B: 1a (NSC73306) and C: 
1d. D: Selectivity ratios of the obtained IC50 values on P-gp (+) and (-) cells for the 
investigated isatin-β-thiosemicarbazones; black: MES-SA/Dx5 vs. MES-SA cells, grey filled: 
MES-SA/Dx5 vs. MES-SA cells in presence of 1 µM TQ, blue: KB-V1 vs. KB-3-1 cells, 
green: A2780adr vs. A2780. Significance of the difference between P-gp (+) and P-gp (-) 
cells was calculated using paired t-tests and is given as *: p ≤ 0.05, **: p ≤ 0.01, ***: p ≤ 
0.001, ****: p ≤ 0.0001. E: P-gp negative fraction of MES-SA/Dx5 cells (as determined by 
the Calcein AM assay, see Methods [67]) at the beginning of the experiment (t=0), after long-
term culture without treatment (contr) or treated with the IC20 concentrations of 1a, 1c or 1d. 
F-H: Immunocytochemical staining of cells. P-gp expression (MRK-16, red) of MES-SA/Dx5 
cells (G) is restored to baseline levels (MES-SA cells, F) after 5 rounds of treatment with 1d 
(H). Nuclei are stained with DAPI (blue); bar=20 micrometers. 
 
Figure 4. SAR matrix of picolinylidene Schiff bases. Biodata was obtained using mCherry 
transfected MES-SA and MES-SA/Dx5 cells, average pIC50 values of three independent 
experiments are shown with the color coding as indicated. 
 
Figure 5. Effect of imino methylation on toxicity. Pairwise comparison of pIC50 values from 
MMPs of chelators containing NNS (A) and NNN (B) donor atom sets obtained in A2780wt 
(open circles), A2780adr (filled circles), KB-3-1 (open triangles), KB-V1 (filled triangles), 
MES-SA (open squares), MES-SA/Dx5 (filled). Cyan: 2f vs. 2g, green: 4a vs. 4b, blue: 5a vs. 
5b, bordeaux: 2n vs. 2o, pink: 2l vs. 2m, orange: 4e vs. 4f, red: 4g vs. 4h, (see Table S3 – S6 
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for details). C: Box and Whiskers plot of toxicity data on MES-SA-mCh and MES-SA/Dx5-
mCh cells comparing NNN and NNS chelators with (blue) and without (cyan) methylation at 
the imino carbon (p=0.045). 
 
Figure 6. Structure-activity relationship matrix (SARM). Average pIC50 values of at least 
three independent experiments are shown for the A2780, KB and MES-SA cell pairs 
according to the arrangement shown in the inset. In general, data are obtained by MTT assays, 
those compounds marked with an asterisk were measured by the fluorescent cytotoxicity 
assay only. Data for 4a-c are taken from Pape et al. [13]. 
 
Figure 7. Toxicity of picolinylidene (class V) and salicylidene (class VI) hydrazinobenzothia-
zole ligands. Biodata was obtained using mCherry transfected MES-SA and MES-SA/Dx5 
cells, pIC50 values are shown with the color coding as indicated. 
 
Figure 8. Influence of donor atom sets on toxicity: A: pairwise comparison of pIC50 values 
from matched molecular pairs (MMP) with ONS and NNS donor sets obtained in A2780wt 
(open circles), A2780adr (filled circles), KB-3-1 (open triangles), KB-V1 (filled triangles), 
MES-SA (open squares), MES-SA/Dx5 (filled squares). Different colors indicate the 
respective compound pairs: Cyan: 6a vs. 5a, green: 6b vs. 5b, blue: 3c vs. 2f, purple: 3d vs. 
2g, orange: 3a vs. 2a, pink: 3e vs. 2m (For details, see Tables S3 - S6). B: Comparison of 
overall toxicity data of ONS (red), NNS (blue) and NNN (green) chelators with and without 
MMPs. Data from mCherry fluorescence measurements using MES-SA and MES-SA/Dx5 
cells are shown (***p ≤ 0.001, ****: p ≤0.0000001). C: activity of ONS (red), NNS (blue) 
and NNN (green) chelators with and without MMPs in P-gp (+) and P-gp (-) cells, averaged 
over all investigated cell lines and assays.  
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Figure 9. Effect of the ONS and NNS donor atoms on toxicity against the NCI60 cell panel. 
Substructure search in the DTP drug database performed for NNS (A) or ONS (B) chelator 
scaffolds retrieved 946 and 389 search results, respectively. Biodata was available for 218 
NNS chelators, 39 NNS compounds without chelating properties, 32 metal binding NNS 
chelators, 34 ONS chelators, 33 non-chelating ONS compounds and 29 ONS-metal 
complexes (see Figure S12). C: Pairwise comparison of cytotoxic activity of matched 
molecular ONS and NNS donor chelator pairs across the NCI60 cell panel. Structures of the 
compounds are shown below the graph (data for X = C-OH (red) or N (blue)). NSC95678 
contains both binding options (purple). D: Average toxicity of the compounds identified by 
the substructure search (pIC50 values averaged over the 60 cell lines). 
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Supporting Information:  
Table S1: Reported MDR selective isatin-β-thiosemicarbazones identified in the DTP 
database [15]  
Tables S2-S6: Predicted physicochemical properties and measured biological data of isatin β-
TSCs (Table S2), pyridinecarbaldehyde TSCs (Table S3), salicylaldehyde TSCs (Table S4), 
arylhydrazones (Table S5) and hydrazinobenzothiazoles (Table S6). 
Tables S7-S8: Correlation of toxic activity to physicochemical properties of pyridinylidense 
Schiff bases from Figure 4 (Table S7), and hydrazinobenzothiazoles from Figure 7B (Table 
S8). 
Figure S1: Comparison of toxicity in cancerous cell lines vs. non-cancerous HFF fibroblast 
cells. 
Figure S2: Comparison of MTT and mCherry assay results on MES-SA and MES-SA/Dx5 
cells using 35 different compounds. 
Figure S3-S7: Box and Whiskers plots of selectivity ratios (SR) of isatin β-TSCs (Figure S3 
A), pyridinecarbaldehyde TSCs (Figure S4), salicylaldehyde TSCs (Figure S5), 
arylhydrazones (Figure S6) and hydrazinobenzothiazoles (Figure S7). Cell growth and 
schedule for long term treatment with IC20 concentration of 1d (Figure S3 B) and histograms 
characterizing the cells with Calcein AM assay (Figure S3 C-F). 
Figure S8: Effect of Tariquidar on toxicity of investigated compounds. 
Figure S9: Comparison of toxicity data for chelators with and without imino-methylation 
obtained in P-gp positive vs. negative cell lines. 
Figure S11: Comparison of toxicity data for chelators with different donor atom sets obtained 
in P-gp positive vs. negative cell lines. 
Figure S12: Flowchart of the identification of NNS (A) and ONS (B) donor chelators in the 
DTP database. C: example for a non-chelating NNS molecule NSC656776; D: outstandingly 
toxic non chelating ONS molecules. 
Figure S13: Refinement of search results from Figure F with respect to imino carbon 
substitution. 
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Figures S14-S19: Representative 1H (A) and 13C (B) spectra of compounds 2c, 2j, 3b, 5c, 6b, 
and 7c. 
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Table 1. Compounds showing increased toxicity in MDR cells. 
Selectivity ratios (SR) were determined as the fraction of IC50 values obtained in 
P-gp negative vs. positive cells. The median of SR values obtained in at least 3 
independent experiments (see Figures S2 – S6 for experimental data) is given for 
the respective test systems. The effect is considered P-gp dependent, if inhibition 
of the transporter (as achieved by TQ coadministration, see Figure S7) abolishes 
MDR-selective toxicity 
Compound Cell lines median 
SR [b] 
Effect of P-gp inhibition 
on MDR selectivity 
1a MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
KB-3-1 / KB-V1 
A2780 / A2780adr 
1.87 
3.17 
2.04 
1.60 
yes 
yes 
yes (not shown) 
yes (not shown) 
1b MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
2.31 
3.29 
yes 
yes 
1c MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
1.87 
3.1 
no 
yes 
1d MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
KB-3-1 / KB-V1 
A2780 / A2780adr 
1.77 
3.55 
1.82 
2.98 
yes 
yes 
yes (not shown) 
yes (not shown) 
1e MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
1.44 
2.42 
yes 
yes 
2c MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
22.59 
4.54 
no 
no 
2f MES-SA / MES-SA/Dx5 [a] 4.55 no 
2g MES-SA / MES-SA/Dx5 [a] 
KB-3-1 / KB-V1 
6.25 
1.15 
no 
no (not shown) 
3a MES-SA / MES-SA/Dx5 [b] 2.23 no 
4b MES-SA / MES-SA/Dx5 [a] 
A2780 / A2780adr 
2.62 
4.33 
no (not shown) 
no (not shown) 
4c MES-SA / MES-SA/Dx5 [a] 
A2780 / A2780adr 
1.41 
2.03 
no 
no (not shown) 
5a MES-SA / MES-SA/Dx5 [a] 1.41 - 
5b MES-SA / MES-SA/Dx5 [a] 17.58 no 
5c MES-SA / MES-SA/Dx5 [a] 1.68 - 
5d MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
1.64 
2.41 
- 
- 
6a MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
2.04 
7.18 
no 
yes 
6b MES-SA / MES-SA/Dx5 [a] 
MES-SA / MES-SA/Dx5 [b] 
1.91 
1.90 
no 
no 
6d MES-SA / MES-SA/Dx5 [b] 4.71 no 
6e MES-SA / MES-SA/Dx5 [b] 5.65 no 
[a] MTT. [b] mCherry 
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Highlights 
• A focused library of ONS, NNS and NNN donor chelators was designed and 
synthesized 
• Thiosemicarbazones, arylhydrazones and hydrazinobenzothiazoles were investigated 
• In vitro antiproliferative activity was tested in sensitive and MDR cancer cells 
• Molecular features influencing the toxicity of anticancer chelators were identified 
 
 
